Cryoport Inc (CYRX) FinancialsCYRXFinancialCryoport Inc

Cryoport, Inc. (CYRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is BioLogistics solutions, accounting for 45.7% of total sales, equivalent to $22.36M. Other significant revenue streams include Life Science products and BioStorage/Bioservices. Understanding this composition is critical for investors evaluating how CYRX navigates market cycles within the Courier, Postal, Air Freight & Land-based Logistics industry.

Evaluating the bottom line, Cryoport, Inc. maintains a gross margin of 46.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -20.50%, while the net margin is -16.86%. These profitability ratios, combined with a Return on Equity (ROE) of -8.88%, provide a clear picture of how effectively CYRX converts its operational activities into shareholder value.

In the context of the broader market, CYRX competes directly with industry leaders such as RLGT and FLX. With a market capitalization of $772.40M, it holds a leading position in the sector. When comparing efficiency, CYRX's gross margin of 46.61% stands against RLGT's 24.61% and FLX's 10.16%. Such benchmarking helps identify whether Cryoport, Inc. is trading at a premium or discount relative to its financial performance.

Cryoport's revenue has shown a strong upward trend, with Q1 2026 revenue at $47.8 million, exceeding estimates, and a gross margin of 46.61% in Q2 2026, reflecting solid profitability potential despite recent losses.